Thirty-four patients diagnosed with breast cancer were included in a prospective study evaluating the bone marrow (BM) CD34
In the setting of autologous peripheral blood progenitor cell transplantation (PBPCT) there is wide interindividual variation in the ability to mobilize progenitors and, consequently, in the peripheral blood (PB) CD34 + harvest and subsequent engraftment. Nevertheless, few data exist concerning parameters that permit the estimation of the overall yield of mobilized and collected hemopoietic cells prior to the initiation of priming schedules. Both previous radiochemotherapy treatments 1, 2 and steady-state PB CD34 + cell count 3 have been reported to be related to the yield of hematopoietic cells after mobilization protocols.
Considering that the bone marrow (BM) CD34 + /CD71 − subset is enriched in multipotent hematopoietic progenitors and in the most immature myeloid progenitors, [4] [5] [6] [7] we performed the present study with the aim of evaluating whether the pre-mobilization BM content of such a subpopulation could be related to the subsequent CD34 + cell release to PB following rG-CSF administration.
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Materials and methods
Thirty-four patients who had histologically proven breast cancer (29 stage II or III, and five stage IV) (mean age 43, range 29-62 years) included in a PBPCT program entered the study. Stage II or III patients had received five to eight cycles of chemotherapy using CEF (cyclophosphamide, 600 mg/m 2 , day 1; epirubicin, 90 mg/m 2 , day 1; 5-fluorouracil, 600 mg/m 2 , day 1), while patients with stage IV breast cancer had been treated with different regimens of induction chemotherapy.
All 34 patients underwent bone marrow aspiration 2-4 weeks before the initiation of the mobilization schedule. Aspirated marrow was resuspended in 199 media (GIBCO, Life Technologies, Paisley, UK) and 5% heparin.
Patients received rG-CSF (Filgrastim; Amgen, Thousand Oaks, CA, USA) s.c. at a dose of 10 g/kg/day. A 10-liter leukapheresis procedure was performed 14-18 h after the third dose of the cytokine using a Fenwall CS 3000 Plus blood cell separator (Fenwall, Deerfield, IL, USA), and daily for 2-4 days until the collected mononuclear count exceeded 6 × 10 8 /kg. Two patients underwent one single apheresis, 18 patients required two PBPC collections, and three procedures were performed in 14 patients. Evaluation of hematopoietic progenitors is based on a total of 80 single leukapheresis product samples. Processing of samples for immunofluorescence analysis was essentially performed as previously reported. 8 Bone marrow samples were stained with PE-conjugated CD34 (anti-HPCA-2), and FITC-conjugated CD71 (anti-transferrin receptor); mononuclear cells from cytapheresis samples were stained with FITC-conjugated CD34 (anti-HPCA-2). In both cases, irrelevant isotype controls were used (all monoclonal antibodies are from Becton Dickinson, Mountain View, CA, USA). Fifty thousand mononuclear cells were gated by forward and side scatter signals using a FACScan (Becton Dickinson) with Lysis 2.0 Software. Data analysis was performed with Paint-A-Gate Plus Software, and the percentage of nonspecific events was substracted from positive events in stained samples.
In order to assess statistical significance the two-tailed unpaired Student's t-test was used. Estimation of correlation was performed using the Spearman's correlation coefficient. Results are given as mean Ϯ standard error of means (s.e.m.), and range values. A significance level of P Ͻ 0.05 was chosen.
Results

CD34
+ and CD34 + /CD71 − events in the analyzed live gate was 0.94 Ϯ 0.14%, ranging from 0.07 to 3.79% (35-1895 positive events), which corresponded to a range of 0.04-1.01% in the whole bone marrow sample.
CD34 cell counts in apheresis collections
The content of the collected CD34
+ cell subset in the leukapheresis products was 2.63 Ϯ 0.19 × 10 
Correlation of BM CD34
+ /CD71 − but not CD34 + cell concentration with CD34
+
cells in apheresis collections
The concentration of CD34 + /CD71 − cells in BM correlated with the absolute number of CD34 + cells in the PB collected material (P = 0.005, r = 0.47). This BM cell subset also correlated with the CD34 + cell concentration in aphereses 1 + 2 and in apheresis 1 (P = 0.01, r = 0.42 and P = 0.03, r = 0.36, respectively).
The statistical comparison between BM CD34 + and the total PB harvested CD34 + cells showed no correlation (P = 0.074, r = 0.32), and did not correlate with the CD34 + cell concentration in aphereses 1 + 2 (P = 0.16, r = 0.27) and in apheresis 1 (P = 0.33, r = 0.19).
BM CD34
+ /CD71 − cell concentration Ͼ or Ͻ30/l relate to differences in collected CD34 cells
When separating patients into two groups according to the reservoir of BM CD34
+ /CD71 − cells prior to rG-CSF administration (Ͼ30/l and Ͻ30/l), a significant association with the number of total CD34 + cells collected was found (3.12 × 10 6 /kg and 2.19 × 10 6 /kg, respectively), P = 0.013 (Table 1) . In like manner, CD34
+ cell yields in PB collections Ͼ3 × 10 
Discussion
The estimation of an individual's potential to mobilize progenitors would help to optimize decisions on when, how and how much to prime in order to maximize the efficacy of PBPC collections. Previous studies evaluating such predictive parameters have been focused, among others, on the amounts of radio-chemotherapy prior to PBPCT as markers of medullary toxicity [1] [2] [9] [10] [11] or type and doses of chemotherapy/cytokines in priming schedules. 12, 13 Others have found that steady-state PB CD34
+ cells correlate with the yield of mobilized progenitors collected for transplantation. 3 However, there are technical difficulties associated with the quantitation of very low numbers of CD34 + cells found in steady-state PB that render information regarding steady-state subsets in BM more reliable. Nevertheless, Fruehauf et al 3 found no association between either the BM total CD34
+ cells, the BM mature committed CD34 + /CD33 + and CD34 + /CD45RA + cell subpopulations, or in the medullary content of the heterogeneous CD34 + /HLA-DR − cell subset, and the mobilization outcome.
In the present study, restricted to a homogeneous group, in terms of previous chemotherapy and mobilization schedule, of breast cancer patients, we have measured the BM steady-state content of CD34 + /CD71 − cells, a subpopulation which is enriched in multipotent hematopoietic progenitors and the most immature myeloid progenitors. [4] [5] [6] [7] Thus, reasoning that this BM cell subset could be associated with the proliferative response after rG-CSF priming and subsequent migration to PB, we quantitated the content of CD34 + cells in the leukapheresis preparations. Our results show a significant correlation between BM CD34 + /CD71 − cell concentration and both the total CD34 + cells collected or the CD34 + cell concentration considering both the yields of aphereses 1 or apheresis 1 + 2.
In accordance with other authors, 3 no association was found between BM CD34 + cells and the apheresis yield. As human hematopoietic progenitor cells constitute a heterogeneous cell population in which most of the cells are already committed to a particular lineage, the effect of rG-CSF on most of these committed progenitors would probably be reflected in the release of myeloid CD34 − cells, whereas the primitive subsets of cells with multilineage capabilities might be mainly responsible for the medullary expansion and subsequent release of CD34 + cells to PB. Our data reveal that BM concentration of CD34 + /CD71 − cells Ͼ30 l is significantly associated with higher CD34 + cells in the collected material (mean value 3.12 × 10 6 /kg). Such a threshold might be considered to be a safe concen-tration for the initiation of rG-CSF priming and subsequent collection. The finding of lower steady-state BM CD34
+ /CD71 − concentrations may help to support the use of more aggressive or effective mobilization schedules, or a later and more optimal time for starting priming and collection.
In conclusion, these results indicate that steady-state BM CD34
+ /CD71 − cell concentration might be considered a relevant predictive parameter of the CD34 + cell yield after rG-CSF administration.
